{
    "nct_id": "NCT06510374",
    "official_title": "A Phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer",
    "inclusion_criteria": "* Diagnosed with intermediate risk non-muscle invasive bladder cancer (IR NMIBC) as defined by American Urological Association (AUA)/Society of Urologic Oncology [SUO] Guideline (2020)\n* Has undergone complete transurethral resection of bladder tumor (TURBT; with or without peri-operative chemotherapy) within 60 days prior to randomization:\n\n  * Recurrence within 1 year, low-grade Ta\n  * Solitary low-grade Ta >3 cm\n  * Low-grade Ta, multifocal\n  * Solitary high-grade Ta, ≤3 cm\n  * Low-grade T1\n\n    * Restage TURBT may be done at the discretion of the investigator\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Current or previous evidence of muscle invasive (muscularis propria) or metastatic disease presented at the screening visit\n\nHigh risk NMIBC defined as:\n\n* High-grade T1\n* Any recurrent, high-grade Ta\n* High-grade Ta >3 cm (or multifocal)\n* Any carcinoma in situ (CIS)\n* Any Bacillus Calmette-Guérin (BCG) failure in high-grade subject\n* Any variant histology\n* Any prostatic urethral involvement\n\nLow risk NMIBC defined as:\n\n* First occurrence of low-grade solitary Ta ≤3 cm\n* Recurrence of low-grade solitary Ta ≤3 cm >12 months from previous occurrence\n* Papillary urothelial neoplasm of low malignant potential",
    "miscellaneous_criteria": ""
}